About Forward MomentumThis author has not yet filled in any details.
So far Forward Momentum has created 33 blog entries.
Movember and Alberta Cancer Foundation campaigns boost prostate cancer screening studyForward Momentum2022-01-04T19:11:01+00:00
News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.
Cowpea mosaic virus nanoparticles for cancer imaging and therapyForward Momentum2022-01-04T18:55:06+00:00
Nanoparticle platforms are attractive for theranostic applications due to their multifunctionality and multivalency. Some of the most promising nano-scale scaffolds have been co-opted from nature, such as the cowpea mosaic virus (CPMV). What makes CPMV so promising? They are non-infectious and nontoxic to humans and safe for use in intravital imaging and drug delivery. Click on the link to read more.
AUTHOR: PERRIN BEATTY AND JOHN LEWIS
ClarityDX Prostate clinical validation study is expanding into the US with Century Clinical Research, Inc.Forward Momentum2022-01-04T19:11:32+00:00
The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.
Nanostics featured on Alberta Impact Episode 5 with Bryce LambertForward Momentum2022-01-04T19:12:04+00:00
1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.
The Cancer Consortium-Nanostics: Advanced Machine Learning to Detect Prostate CancerForward Momentum2022-01-04T19:12:39+00:00
Nanostics’ core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.
Prostate Cancer News Today: Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test.Forward Momentum2022-01-04T19:13:18+00:00
Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.
Faculty of Medicine & Dentistry: U of A spin-off company Nanostics launches clinical validation study for ClarityDX ProstateForward Momentum2022-01-04T19:13:46+00:00
NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.
Nanostics and DynaLIFE productive partnership – video interview with Edmonton JournalForward Momentum2022-01-04T19:14:37+00:00
CSO Desmond Pink discusses Nanostics’ productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.
PROSPeCT: A Predictive Research Online System for Prostate Cancer TasksForward Momentum2022-01-04T18:55:55+00:00
We are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs (www.APCaRI.ca) robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in the Journal of Clinical Oncology – Clinical Cancer Informatics. Thank you to the Alberta Cancer Foundation and many others for their support.
AUTHOR: AUTHOR: MARIA CUTUMISU, CATALINA VASQUEZ, MAXWELL UHLICH, PERRIN H. BEATTY, HOMEIRA HAMAYELI-MEHRABANI, RUME DJEBAH, ALBERT MURTHA, RUSSELL GREINER, AND JOHN D. LEWIS